Today we’re unveiling our new Scientific Advisory Board (SAB), which brings together five leading European cancer experts to help fast-forward our growth. The SAB is a multi-disciplinary formation with cross-cutting knowledge across some of the most advanced areas in cancer research and clinical development.
Importantly, all of its members already know our team well, as we have collaborated together on many projects over several years both as invIOs and APEIRON Biologics AG.
Our CMSO Romana Gugenberger explains:
“The formation of our Scientific Advisory Board is a major step in invIOs’s development as a leading Austrian and European developer of novel cancer immunotherapies. Individually, each member of the SAB brings world-class expertise and deep knowledge in areas at the forefront of immuno-oncology, from novel checkpoint inhibitors to molecular biology to clinical trials. Together, they will help take invIOs to the next level as we seek to accelerate the development of new treatment options for cancer patients worldwide. I’m delighted to welcome them all as members of our Scientific Advisory Board, and look forward to working together even more closely over the coming years.”
In alphabetical order, the members of invIOs’s Scientific Advisory Board are: